论文部分内容阅读
目的评价曲美他嗪治疗不稳定型心绞痛的疗效及其对C-反应蛋白(CRP)的影响。方法我院43例符合标准的不稳定型心绞痛患者随机分为对照组(22例)和治疗组(21例)。对照组患者给予基础治疗(硝酸酯类,β-受体阻滞剂,抗凝剂及阿司匹林等),治疗组在此基础上加用曲美他嗪,疗程均为4周。治疗前、后进行心电图检查,记录心绞痛发作次数及每次心绞痛发作的时间,同时检测治疗前后血清C-反应蛋白含量。结果两组患者临床疗效差异有统计学意义(P<0.05)。两组患者治疗后心绞痛发作次数、持续时间、C-反应蛋白含量差异均有统计学意义(P<0.05)。结论曲美他嗪可明显改善不稳定型心绞痛患者临床疗效,显著降低不稳定型心绞痛患者血清CRP水平。
Objective To evaluate the efficacy of trimetazidine in the treatment of unstable angina pectoris and its effect on C-reactive protein (CRP). Methods Forty-three patients with unstable angina pectoris in our hospital were randomly divided into control group (n = 22) and treatment group (n = 21). Patients in the control group were given basic treatment (nitrates, β-blockers, anticoagulants and aspirin, etc.). The treatment group was given trimetazidine on the basis of the above treatment for 4 weeks. Before and after treatment, electrocardiogram was performed to record the number of angina pectoris episodes and angina pectoris time, meanwhile, serum C-reactive protein level was measured before and after treatment. Results There was a significant difference in clinical efficacy between the two groups (P <0.05). The number of angina attacks, duration and C-reactive protein content after treatment in both groups were significantly different (P <0.05). Conclusion Trimetazidine can significantly improve the clinical efficacy of patients with unstable angina and significantly reduce the serum CRP levels in patients with unstable angina.